Mitragynine: Pharmacology, Safety, and Clinical Evidence
Evidence-based review of mitragynine covering pharmacokinetics, metabolism to 7-hydroxymitragynine, mu-opioid mechanisms, safety profile, dependence liability, and the critical distinction between traditional leaf and concentrated products.
Important Safety Notice
This content is for educational and research purposes only. It is not medical advice or guidance on the use of kratom or any kratom-derived product. Kratom and its alkaloids are not FDA-approved for any medical use. Serious adverse effects — including dependence, withdrawal, liver injury, seizures, respiratory depression, and rare severe outcomes — have been reported.
Evidence Snapshot
This table scrolls horizontally on small screens. Use Tab to focus the table region, then scroll with arrow keys or touch.
| Outcome | Human evidence | Conservative interpretation |
|---|---|---|
| Pharmacokinetics | Limited-moderate | Leaf-powder PK data exist, but product forms vary widely |
| Pain-related outcomes | Limited | Signals exist; controlled efficacy evidence remains thin |
| Opioid-withdrawal self-management | Limited | Observational reports exist; dependence from kratom itself is documented |
| Mood and anxiety | Limited | Mostly survey-level evidence; insufficient for therapeutic claims |
| Long-term safety | Limited | Dependence, withdrawal, liver injury, seizures, and severe events remain concerns |
For related profiles: 7-hydroxymitragynine and the mitragynine vs 7-OH comparison.
Pharmacokinetics and Metabolism
Mitragynine is the most abundant indole alkaloid in kratom (Mitragyna speciosa) leaf. It acts as a partial agonist at the mu-opioid receptor with lower intrinsic efficacy than morphine and other full agonists, plus relatively limited beta-arrestin recruitment compared with classical opioids.
A 2024 double-blind, placebo-controlled PK study in healthy volunteers found [1]:
- Tmax: ~1.0–1.3 hours after single oral doses of encapsulated leaf powder
- Half-life: ~43 hours after single doses; longer with repeated administration
- Steady-state: approached within 8–9 days of daily dosing
- 7-OH conversion: measurable plasma concentrations of 7-hydroxymitragynine appeared after oral dosing, with 7-OH-to-mitragynine ratios of ~0.20–0.31
This metabolic conversion — mediated primarily by CYP3A4 — is the critical pharmacokinetic feature. 7-hydroxymitragynine has substantially higher mu-opioid potency and efficacy than mitragynine. The rate-limited nature of this conversion may create a ceiling effect on certain outcomes, including respiratory depression [3], but does not eliminate risk.
Key implications:
- CYP3A4 inhibitors, inducers, liver function, product composition, and polydrug use all affect exposure
- Concentrated or semi-synthetic 7-OH products create different — and potentially more dangerous — exposure patterns than traditional leaf
- Traditional leaf and concentrated 7-OH products are not interchangeable for risk assessment
Mechanisms
Mitragynine interacts with mu-, kappa-, and delta-opioid receptors, plus adrenergic and serotonergic targets. Its partial mu-agonism and limited beta-arrestin recruitment partially explain the lower respiratory depression versus full agonists in some experimental models — but relative difference is not the same as safety.
The metabolic conversion to 7-hydroxymitragynine introduces a major variable: the overall pharmacodynamic profile of leaf preparations (mitragynine-dominant, rate-limited 7-OH formation) may differ substantially from products that deliver high levels of 7-OH directly.
Safety and Toxicology
Respiratory Effects
Available data suggest less pronounced respiratory depression than classical full mu-agonists in experimental models. However, respiratory depression and overdose have been reported, especially with concentrated products, elevated 7-OH content, or co-use with alcohol, benzodiazepines, opioids, gabapentinoids, or other CNS depressants. "Less pronounced" is not "safe."
Dependence and Withdrawal
Both preclinical and human data indicate repeated mitragynine exposure can produce physical dependence. Withdrawal symptoms overlap with classical opioid withdrawal. Severity correlates with dose, duration, frequency, and product potency. Dependence liability appears higher with concentrated or high-dose regimens and products containing elevated 7-OH.
Other Serious Events
Case reports and surveillance data have linked kratom alkaloids to liver injury, seizures, cardiovascular events, and deaths — often with polydrug exposure or unclear causality. The FDA continues to warn about kratom-related risks [5] and has taken enforcement actions involving concentrated 7-OH products [6].
Traditional Leaf vs. Concentrated Products
This table scrolls horizontally on small screens. Use Tab to focus the table region, then scroll with arrow keys or touch.
| Traditional leaf | Concentrated / high-7-OH products | |
|---|---|---|
| Alkaloid profile | Mitragynine-dominant, mixed matrix | Often enriched or altered |
| 7-OH exposure | Trace natural content + metabolic formation | Higher direct exposure possible |
| Human data | Limited, mostly leaf/user studies | Very limited for isolated products |
| Dependence risk | Present | Potentially higher |
| Regulatory status | Not FDA-approved; risks documented | Especially high scrutiny; FDA enforcement active |
Research Gaps
- Larger controlled trials with standardized products
- Long-term safety data (liver, cardiovascular, dependence trajectories)
- CYP3A4 variability and drug-drug interaction studies
- Better characterization of withdrawal syndrome severity and duration
- Direct comparisons of leaf vs. concentrated product risk profiles
FAQ
Is mitragynine the same as kratom? No. Mitragynine is one major alkaloid in kratom leaf. Kratom contains a wider alkaloid mixture with substantial product variability.
Is mitragynine the same as 7-hydroxymitragynine? No. Mitragynine can be metabolized into 7-OH, which is more potent at the mu-opioid receptor.
Is mitragynine FDA-approved? No. There are no FDA-approved kratom products legally marketed in the United States.
Does lower respiratory depression risk mean mitragynine is safe? No. Relative differences versus classical opioids do not eliminate dependence, withdrawal, liver, seizure, cardiovascular, or polydrug risks.
Educational purposes only. Does not replace professional medical advice.
References
- Huestis MA, Brett MA, Bothmer J, Atallah R Human Mitragynine and 7-Hydroxymitragynine Pharmacokinetics after Single and Multiple Daily Doses of Oral Encapsulated Dried Kratom Leaf Powder (2024) — Source
- Kruegel AC, et al. 7-Hydroxymitragynine Is an Active Metabolite of Mitragynine and a Key Mediator of Its Analgesic Effects (2019) — Source
- U.S. Food and Drug Administration FDA and Kratom (2026) — Source
- U.S. Food and Drug Administration FDA Seizes 7-OH Opioids to Protect American Consumers (2025) — Source